Clinical Trials Directory

Trials / Completed

CompletedNCT04649970

Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy

Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy: a Single Center Experience

Status
Completed
Phase
Study type
Observational
Enrollment
174 (actual)
Sponsor
Université de Sousse · Academic / Other
Sex
All
Age
Healthy volunteers

Summary

Ureteral double- J stent is usually inserted by retrograde approach for the treatment of obstructed upper urinary tract. The antegrade approach, can a suitable alternative in certain situations without the need for general or spinal anesthesia. The present study demonstrates the indications, success rate, and complications of this approach in the treatment of malignant obstructive uropathy.

Detailed description

Data of consecutive patients in whom antegrade ureteral stent¬ing was performed between January 2013 and February 2020 were retrospectively analysed using patient records and radiology reports. A total of 174 patients (sexe ratio = 0.51, age range 9-91 years; mean age, 54 years) were included in the study. Ureteral obstruction was caused by bladder cancer (n=92), uterin cancer (n=31), prostate cancer (n=28), colorectal cancer (n= 15) and retroperitoneal tumor (n= 8) (Table 1).

Conditions

Interventions

TypeNameDescription
PROCEDUREAntegrade double-J stentAfter exchanging the nephrostomy catheter over the J-tipped guidewire, 5 F multipurpose (45° tip) diagnostic vascular catheter was inserted. Once the pelvi¬ureteric junction was crossed and the ureter accessed, a straight hydrophilic guidewire and a catheter were used. Then, the cath-eter was advanced into the bladder over the wire, this guidewire was exchanged for an ultra-stiff guidewire, an 8 or 10 F double J ureteral stent was placed over the guidewire, and the safety kit of the stent was removed. A final fluoroscopic image was stored for correcting the stent position.

Timeline

Start date
2013-01-01
Primary completion
2017-06-29
Completion
2020-02-02
First posted
2020-12-02
Last updated
2020-12-04

Source: ClinicalTrials.gov record NCT04649970. Inclusion in this directory is not an endorsement.